MERIDIA CAPSULE

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE

可用日期:

ABBOTT LABORATORIES, LIMITED

ATC代码:

A08AA10

INN（国际名称）:

SIBUTRAMINE

剂量:

10MG

药物剂型:

CAPSULE

组成:

SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE 10MG

给药途径:

ORAL

每包单位数:

30

处方类型:

Prescription

治疗领域:

ANOREXIGENIC AGENTS & RESPIRATORY AND CEREBRAL STIMULANTS, MISCELLANEOUS

產品總結:

Active ingredient group (AIG) number: 0142562001; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2010-10-12

产品特点

_MERIDIA_
_®_
_ Product Monograph _
_Page 1 of 46 _
_ _
PRODUCT MONOGRAPH
PR
MERIDIA
®
sibutramine hydrochloride monohydrate
10 mg and 15 mg capsules
Anorexiant / Antiobesity Agent
Abbott Laboratories, Limited
Date of Revision:
8401 Trans-Canada Highway
November 26, 2009
St-Laurent, Qc H4S 1Z1
Submission Control No: 130400
_MERIDIA_
_®_
_ Product Monograph _
_Page 2 of 46 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................6
WARNINGS AND
PRECAUTIONS..................................................................................7
ADVERSE
REACTIONS..................................................................................................11
DRUG INTERACTIONS
..................................................................................................17
DOSAGE AND
ADMINISTRATION..............................................................................20
OVERDOSAGE
................................................................................................................22
ACTION AND CLINICAL PHARMACOLOGY
............................................................22
STORAGE AND
STABILITY..........................................................................................26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................26
PART II: SCIENTIFIC INFORMATION
................................................................................27
PHARMACEUTICAL
INFORMATION..........................................................................27
CLINICAL
TRIALS..........................................................................................................27
D